Safety and Efficacy of AK104, a PD-1/CTLA-4 Bispecific Antibody, in Selected Advanced Solid Tumors

Name: Safety and Efficacy of AK104, a PD-1/CTLA-4 Bispecific Antibody, in Selected Advanced Solid Tumors
Published: 2019
License: Public Domain

Akeso · 2019

ClinicalTrials.gov · Datasets · License: Public Domain · 2019

Open Source ↗

melanoma pd

advanced solid tumors, melanoma, bispecific, pd1/ctla4, pd-1/pd-l1 relapsed/refractory tumors, interventional, phase1, phase2

This document is indexed with metadata only — full text is not available in the archive for this record. Open the official source ↗

Safety and Efficacy of AK104, a PD-1/CTLA-4 Bispecific Antibody, in Selected Advanced Solid Tumors

Related documents